mdx-210

mAbexperimentalMulti-specific

Clinical trial activity

0 trials · 0 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Receptor protein-tyrosine kinase erbB-2INHIBITOR
ERBB2 inhibitor
- Receptor tyrosine-protein kinase erbB-2 (ERBB2) ↗
Receptor protein-tyrosine kinase erbB-2CROSS-LINKING AGENT
Receptor protein-tyrosine kinase erbB-2 cross-linking agent
Immunostimulant. Induces antibody dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC).
- Receptor tyrosine-protein kinase erbB-2 (ERBB2) ↗
High affinity immunoglobulin gamma Fc receptor ICROSS-LINKING AGENT
High affinity immunoglobulin gamma Fc receptor I cross-linking agent
Immunostimulant. Antibody dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC).
- High affinity immunoglobulin gamma Fc receptor I (FCGR1A) ↗
High affinity immunoglobulin gamma Fc receptor IINHIBITOR
FCGR1A inhibitor
- High affinity immunoglobulin gamma Fc receptor I (FCGR1A) ↗
Receptor protein-tyrosine kinase erbB-2OTHER
ERBB2 other
Immunostimulant. Induces antibody dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC).
- Receptor tyrosine-protein kinase erbB-2 (ERBB2) ↗
High affinity immunoglobulin gamma Fc receptor IOTHER
FCGR1A other
Immunostimulant. Antibody dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC).
- High affinity immunoglobulin gamma Fc receptor I (FCGR1A) ↗

Oral

Parenteral

Topical